Healthcare / Health Information ServicesNasdaqGS
$3.07
-0.01 (-0.32%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 23% · confianza 25%
FCF escenarios
weak_data · normalized FCF $93.9M · quality 57.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
46/100
C
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.0B
P/E
51.2x
↑EV/EBITDA
7.5x
↓ROE
4.9%
↑Gross Margin
92.8%
↑Debt/Equity
0.88
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2018–2025 · 7 años de histórico normalizado
Revenue CAGR
+18.0%
FCF CAGR
+11.3%
FCF margin
11.8%
FCF / Net income
3.08x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $796.9M · net income $30.4M · FCF $93.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | $796.9M | $796.9M | $792.3M | $750.3M | $766.6M | $745.4M | $550.7M | $388.2M | $249.5M |
| Net Income | $30.4M | $30.4M | $16.4M | $-8.9M | $-32.8M | $-25.3M | $-293.6M | $66.0M | $43.8M |
| EBITDA | $184.4M | $184.4M | $153.9M | $108.8M | $65.2M | $47.9M | $-257.3M | $153.2M | $87.1M |
| EPS | 0.09 | 0.09 | 0.04 | -0.02 | -0.08 | -0.06 | -1.07 | 0.18 | 0.12 |
| Gross Margin | 92.8% | 92.8% | 93.9% | 91.1% | 91.5% | — | — | — | — |
| Operating Margin | 11.0% | 11.0% | 8.3% | -3.6% | 0.2% | 1.8% | -50.1% | 36.0% | 31.0% |
| Net Margin | 3.8% | 3.8% | 2.1% | -1.2% | -4.3% | -3.4% | -53.3% | 17.0% | 17.6% |
| Balance Sheet | |||||||||
| Debt/Equity | 0.88 | 0.88 | 0.75 | 0.93 | 0.88 | 0.79 | 0.93 | -0.61 | — |
| Current Ratio | 1.47 | 1.47 | — | — | — | — | — | — | — |
| Cash Flow | |||||||||
| Free Cash Flow | $93.9M | $93.9M | $113.5M | $82.5M | $91.6M | $174.2M | $110.8M | $81.9M | $44.4M |
| Returns | |||||||||
| ROE | 4.9% | 4.9% | 2.3% | -1.2% | -4.0% | -3.0% | -41.3% | -6.1% | -3.8% |
| Valuation | |||||||||
| P/E | 51.17 | 51.17 | 111.25 | — | — | — | — | — | — |
| EV/EBITDA | 7.47 | 7.47 | 11.96 | 21.06 | 30.04 | — | — | — | — |
| P/B | 1.78 | 1.78 | 2.41 | 2.96 | 2.45 | — | — | — | — |
| Growth & Yield | |||||||||
| Revenue Growth | 0.6% | 0.6% | 5.6% | -2.1% | — | 35.4% | 41.9% | 55.6% | — |
| EPS Growth | 125.0% | 125.0% | 300.0% | 75.0% | — | 94.4% | -694.4% | 50.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
44.7%
EPS terminal req.
$0.27
Spread vs growth
80.3%
5Y implied EPS CAGR
29.6%
EPS terminal req.
$0.33
Spread vs growth
95.4%
10Y implied EPS CAGR
19.4%
EPS terminal req.
$0.53
Spread vs growth
105.6%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-19.6%
Start / end P/E
95.5x → 34.1x
EPS bridge
0.04 → 0.09
Residual
-80.4%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.